Conditional Recommendations for Specific Dietary Ingredients as an Approach to Chronic Musculoskeletal Pain: Evidence-Based Decision Aid for Health Care Providers, Participants, and Policy Makers

Courtney Boyd, MA,* † Cindy Crawford, BA,* † Kevin Berry, MD,‡ Patricia Deuster, PhD,* and the HERB Working Group

*Consortium for Health and Military Performance, Department of Military & Emergency Medicine, F. Edward Hebert School of Medicine, Uniformed Services University, Bethesda, Maryland, USA; †The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA; ‡Thought Leadership and Innovation Foundation, McLean, Virginia, USA

Correspondence to: Courtney Boyd, MA, Consortium for Health and Military Performance, 6720B Rockledge Dr., Suite 605, Bethesda, MD, 20817, USA. Tel: 571-310-1197; E-mail: courtney.boyd.ctr@usuhs.edu.

Funding sources: Funding for this work was provided by the Preservation of the Force and Family Behavioral Health Program, Uniformed Services University award number HU0001-15–2-0053.

Disclaimer: The opinions or assertions contained herein are the collective views of the authors and the Holistic Evidence Review Board and are not to be construed as official or as reflecting the views of the Uniformed Services University, US Special Operations Command, or the Department of Defense.

Conflicts of interest: No conflicts of interest existed at the time of the project for any authors or steering committee members making evidence-based recommendations.

Abstract

Objective. Approximately 55–76% of Service members use dietary supplements for various reasons; although such use has become popular for a wide range of pain conditions, decisions to use supplements are often driven by information that is not evidence-based. This work evaluates whether the current research on dietary ingredients for chronic musculoskeletal pain provides sufficient evidence to inform decisions for practice and self-care, specifically for Special Operations Forces personnel. Methods. A steering committee convened to develop research questions and factors required for decision-making. Key databases were searched through August 2016. Eligible systematic reviews and randomized controlled trials were assessed for methodological quality. Meta-analysis was applied where feasible. GRADE was used to determine confidence in the effect estimates. A decision table was constructed to make evidence-informed judgments across factors required for decision-making, and recommendations were made for practice and self-care use. Results. Nineteen dietary ingredients were included. Conditional evidence-based recommendations were made for the use of avocado soybean unsaponifiables, capsaicin, curcuma, ginger, glucosamine, melatonin, polyunsaturated fatty acids, and vitamin D. In these cases, desirable effects outweighed undesirable effects, but there was uncertainty about the trade-offs, either because the evidence was low quality or because benefits and downsides were closely balanced. Conclusions. The evidence showed that certain dietary ingredients, when taken as part of a balanced diet and/or as a supplement (e.g., pill, tablet, capsule, cream), may alleviate musculoskeletal pain with no to minimal risk of harm. This finding emphasizes and reinforces the critical importance of shared decision-making between Operators and their health care providers.

Key Words: Systematic Review; Meta-analysis; Dietary Ingredients; Dietary Supplements; Musculoskeletal Pain
Introduction

Musculoskeletal (MSK) injuries are a leading cause of pain, medical encounters, lost duty time, and disability within the military due to the extreme demands of physical training and combat missions [1–3]. Although MSK pain is typically treated with medications (e.g., nonsteroidal anti-inflammatories [NSAIDs], injections, physical therapy, acupuncture, and other modalities [4]), alternative approaches are needed. Dietary ingredients may be one such option. Dietary supplement use for a wide range of conditions, including pain, has become increasingly popular, with about 70–74% of the general adult population and 55–76% of Service members using dietary supplements for various reasons [5,6]. Despite their popularity, evidence for their use is unclear [7–10], and decisions to use these supplements may be driven by information that is not evidence-based (e.g., advice from peers, family members, and other sources). It is imperative that evidence-based research be used to inform decisions regarding such use to ensure safe and effective management of MSK pain.

As part of the US Special Operations Command’s Preservation of the Force and Family Behavioral Health Program, this project sought to determine whether current research on dietary ingredients for chronic MSK pain could provide sufficient evidence to inform decisions for both practice and self-care use. To achieve this, state-of-the-science evidence methodologies were applied to provide clear, comprehensive, and unbiased information to the Special Operations community and enable key stakeholders and subject matter experts to make evidence-based recommendations to inform policy decisions regarding dietary ingredients for improving pain and pain-related (e.g., psychological health, quality of life) outcomes.

The aim of this article is to describe the resulting evidence-based recommendations made for the use of dietary supplements. This paper is the second in a series of articles [11–13] that detail the methodological approach and relevance of this work to Special Operators, specific evidence-based recommendations, and implications for policy decisions. It is important to note that although formal processes were followed and recommendations made, this is not intended to serve as a formal clinical practice guideline.

Methods

The project’s full methodological approach is detailed within the first of this series of three articles (Supplementary Data: Detailed Methodology) [13]. Briefly, 1) the authors followed the Institute of Medicine guidelines to ensure transparent processes were followed and mitigate any conflicts of interest to carefully select and recruit an unbiased group of key stakeholders and subject matter experts [14]. The committee, named the Holistic Evidence Review Board (HERB), was convened to develop the criteria to inform the clinical question(s), definitions (Table 1) [4,15–19], and factors required for decision-making (Supplementary Data: GRADE Grid); 2) a review team, independent of the HERB, then conducted a series of systematic reviews to assess the current state of the evidence and to explore the safety and efficacy of various dietary ingredients for treating pain and related outcomes (Supplementary Data: Summary Report); 3) the gathered evidence was integrated with the expertise of those subject matter experts; and 4) modified Delphi methods were used to develop evidence-based recommendations for the use of dietary ingredients and priority areas in need of future research following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework [13,20–23]. The series of systematic reviews used to inform recommendations are reported in the Supplementary Data: Summary Report.

Conditional recommendations were made when the desirable anticipated effects outweighed the undesirable effects but there was uncertainty about the trade-offs, either because the key evidence was of low quality or because the benefits and downsides were closely balanced. No recommendations were made either because the quality of the evidence was too low or trade-offs were so closely balanced that any recommendation would be too speculative. Recommendations against the current use of an ingredient, based on available evidence, were made when undesirable anticipated effects outweighed the desirable effects or the downsides clearly outweighed the benefits overall.

Results

Nineteen dietary ingredients were identified and evaluated using systematic review methods (Supplementary Data: Detailed Methodology and Summary Report) [13]. Integrating the evidence with the HERB clinical acumen across the factors required for decision-making, three types of recommendations were ultimately made for these dietary ingredients (Figure 1).

This article details dietary ingredients for which conditional, evidence-based recommendations were ultimately made; recommended ingredients include avocado soybean unsaponifiables (ASU) [24–30], capsaicin [31–41], curcuma [42–51], ginger [52–62], glucosamine [63–68], melatonin [69–71], polyunsaturated fatty acids (PUFA) [72], and vitamin D [73–85].

Although uncertainties remain, thereby precluding any strong recommendations for immediate use, these dietary ingredients, when taken as part of a balanced diet, applied as a cream, or administered as a supplement, may help alleviate pain from chronic MSK conditions and are suggested for use. In these cases, health care providers should be prepared to help individuals make decisions consistent with their own values, and Special
Operators should be aware of the potential benefits and discuss the use of these ingredients with a provider. Because no strong recommendations were made to endorse an ingredient for immediate use without any caveats, there is a need to encourage discussion and debate among stakeholders before policy decisions are made.

Conditional Evidence-Based Recommendations

Table 2 displays the ingredients where conditional recommendations were made, the graded evidence for efficacy as well as safety and other considerations examined when making recommendations. Table 3 details the summary of judgments across factors and resulting recommendations.

Avocado Soybean Unsaponifiables

Avocado soybean unsaponifiables are a natural vegetable extract made from one-third avocado oil and two-thirds soybean oil. ASU are commonly used for osteoarthritis symptoms, as it is believed that they slow down disease progression [86, 87].

Six studies meeting the review’s criteria compared ASU with placebo or chondroitin sulfate in knee and/or hip osteoarthritis populations [24–29]. Studies administered 300 or 600 mg/d of ASU for anywhere from three months to three years (Table 2; Supplementary Data: Summary Report). Conditional recommendations were made (75% weak, in favor; 12.5% none; 12.5% weak, against) for the use of Piascledine\(^R\) 300 (300–600 mg/d), a commercialized brand of ASU, as a dietary supplement for pain and related symptoms.

The low to moderate quality and certainty of the evidence suggests that Piascledine 300 or 600 mg/d is associated with a statistically significant reduction in pain (standardized mean difference [SMD] = –0.60) and improvement in function (SMD = –0.64) as compared with placebo at time points of three to six months’ duration. (Supplementary Data: Summary Report). These desirable anticipated effects appeared to be moderate, whereas any undesirable effects, primarily gastrointestinal complaints noted across all treatment groups, were small to trivial. There was a high degree of statistically significant heterogeneity detected from the pooled studies, as well as risk of bias associated with some studies. Additionally, the small sample sizes reduced the certainty of the evidence evaluated.

Research trials to date appear to consistently report on the use of Piascledine 300, the majority of which are funded by the same entity that supplied the intervention. Although ASU appear to be available over the counter (OTC) and in combination with other “joint health” supplements, evidence to support their use in these formulations is unknown. Resources required for the use of ASU are highly dependent on the type of formulary. For

---

**Table 1. Focused PICOS used to define the narrowed research question: Are there dietary supplements/ingredients that can safely mitigate chronic pain in adults (18+ years old) with musculoskeletal disorders?**

| Population | Any single or multiple (e.g., combination of ingredients) dietary ingredient(s) [18, 19]. |
| Control/comparison | Sham, no treatment and/or active comparator. |
| Outcome(s) | Pain, physical function, sleep, mood (anxiety/depression), stress, cognitive performance, global health, health-related quality of life, behavioral, resource use, adverse events. |
| Study design | Peer-reviewed systematic reviews/meta-analyses and/or randomized controlled trials presented in the English language. |

**PICOS** = Population, Intervention, Comparison, Outcomes and Study Designs.

---

**Conditional Recommendation For**
- Avocado Soybean Unsaponifiables
- Capsaicin
- Curcuma*
- Ginger*
- Glucosamine, Prescription, Over-the-Counter
- Melatonin
- Polysaturated Fatty Acids
- Vitamin D

**No Recommendation**
- Boswellia
- Ginger*
- Rose Hip
- S-adenosyl-L-methionine

**Recommendation Against**
- Collagen
- Creatine
- Devil’s Claw
- L-carnitine
- Methylsulfonylmethane
- Pycnogenol
- Vitamin E
- Willow Bark Extract

*Conditionally recommend use as a food source, not as a dietary supplement, at this time.

---

**Figure 1. Recommendations.**
| Ingredient Evaluated | Comparators | No. Studies/Participants | Populations | Outcomes                                                                 | Evidence | Quality | Adverse Events                                                                 | Considerations                                                                                   |
|----------------------|-------------|--------------------------|-------------|---------------------------------------------------------------------------|----------|---------|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| ASU‡ 300–600 mg/d over 3 mo–3 y | vs placebo¶ | 5/1,150 | Osteoarthritis | Pain reduction, 3–36 mo<br>Pain reduction, 3–6 mo<br>Global function, 3–36 mo<br>Global function, 3–6 mo<br>Patient’s global assessment for improvement, 3–12 mo | SMD (5 trials) = −0.34, 8.5 pts<br>SMD (3 trials) = −0.60, 15 pts<br>SMD (5 trials) = −0.42 | Moderate | Mainly minor gastrointestinal complaints in both groups. No noticeable differences between ASU dosages. Risk to experience any AE: vs placebo: NS; vs drug: insufficient data | • Moderate-quality evidence supports taking ASU 300–600 mg/d to reduce pain, improve function, and reduce medication use over time. <br>• Concern that all evaluated research was on a single-producer commercialized product (i.e., Piascledine) that appeared to be funded by the product’s manufacturer. <br>• Need to investigate whether Piascledine is available and feasible to obtain. <br>• Need more research on OTC version before recommending an OTC version. <br>• Be aware of possible burning sensation upon application, especially at higher doses (0.25%). <br>• Invest in resources in dose response study to understand dose response curve. |
| vs other¶ | 2/621 | Osteoarthritis | Pain reduction, mean 4 wk<br>Patient’s global assessment for improvement, mean 4 wk<br>No. of patients requiring use of medication, 3–36 mo | SMD (8 trials) = −0.56, 14.0 pts<br>SMD (3 trials) = −0.64<br>RD (4 trials) = −0.14<br>RD (3 trials) = −0.13 | High | High | Primarily burning, itching, and irritation reported in both groups; more participants in the capsaicin group seemed to report adverse events compared with the placebo group. Risk to experience any AE: vs placebo: NS; heterogeneity detected vs drug: insufficient data | • High-quality evidence supports capsaicin to reduce pain and recommends it as either a cream or a patch, at lower doses to begin treatment. <br>• Indicated for neuropathic pain as second-line treatment; may also be effective for musculoskeletal pain. <br>• Be aware of possible burning sensation upon application, especially at higher doses (0.25%).<br>• Investigate resources in dose response study to understand dose response curve. |
| Capsaicin‡ Patches (0.1% or 22–37.4 ug/cm²); 4–12 h over 3–4 wk | vs placebo 8/1,139 | Back pain, myofascial/soft tissue pain, TMJ, osteoarthritis, rheumatoid arthritis | Pain reduction, mean 4 wk<br>Patient’s global assessment for improvement, mean 4 wk<br>No. of patients requiring use of medication, 3–36 mo | SMD (8 trials) = −0.56, 14.0 pts<br>RD (7 trials) = −0.21 | Moderate | Primarily burning, itching, and irritation reported in both groups; more participants in the capsaicin group seemed to report adverse events compared with the placebo group. Risk to experience any AE: vs placebo: NS; heterogeneity detected vs drug: insufficient data | • High-quality evidence supports capsaicin to reduce pain and recommends it as either a cream or a patch, at lower doses to begin treatment. <br>• Indicated for neuropathic pain as second-line treatment; may also be effective for musculoskeletal pain. <br>• Be aware of possible burning sensation upon application, especially at higher doses (0.25%).<br>• Investigate resources in dose response study to understand dose response curve. |
| vs other 2/194 | Fibromyalgia, osteoarthritis | Only one study compared capsaicin with another comparator (i.e., usual care). Both high (i.e., 0.25% capsaicin) and low (i.e., 0.025% capsaicin) doses were effective. Although a higher dose may produce more burning sensation, the application of the product may be required less frequently, and preliminary evidence suggests that pain relief occurs quicker at this higher dose. | | | | | | • Investigate resources in dose response study to understand dose response curve. |
Table 2. continued

| Ingredient | Evaluated Comparator | No. Studies/Participants | Populations | Outcomes | Evidence | Quality | Adverse Events | Considerations |
|------------|-----------------------|--------------------------|-------------|----------|----------|---------|----------------|----------------|
| Curcuma*,‡ | vs placebo 3/223‡ | Osteoarthritis | Pain reduction, mean 2 mo | SMD (3 trials) = -1.05, 26.25 pts greater reduction than placebo | Low | Mainly minor gastrointestinal complaints in both groups. Risk to experience any AE: vs placebo: insufficient data vs drug: insufficient data |
| 700–2,000 mg/d over 6–12 wk | Global function, mean 2 mo | | Reliance on medication, mean 2 mo | SMD (3 trials) = -0.87 RD (3 trials) = -0.50 | Very low | |
| vs other 5/727‡ | Osteoarthritis rheumatoid arthritis | Studies (N = 2) comparing curcuma with ibuprofen seemed to indicate improvement in pain over time and, in some cases, more improvement than ibuprofen. Another study also found curcuma to be generally superior to glucosamine sulfate. |

*Studies (N = 3) combining curcuma with other ingredients showed promising results, significantly improving pain and physical function compared with placebo but not celecoxib.

Ginger*,† | vs placebo§ | 6/741 | Osteoarthritis | Pain reduction, mean 2 mo | SMD (5 trials) = -0.30, 7.5 pts greater reduction than placebo | Moderate | Bad taste or various forms of stomach upset; none “serious” but some resulted in trial discontinuation. Risk to experience any AE: vs placebo: 12% greater risk for someone to experience an AE following ginger (RD = 0.12, 95% CI = 0.02, 0.23, P = 0.02, I² = 49.00%) vs drug: insufficient data |
| Capsule: 250–1,000 mg/d over 3–12 wk | Self-reported disability | | | SMD (4 trials) = -0.22 | | |
| Ointment: 6 g/d over 6 wk | vs other§ | 2/187 | Osteoarthritis | Two studies compared ginger with ibuprofen and reported mixed results. The higher the dose (e.g., 1,000 mg), the more likely a positive benefit for ginger only. |

*Studies combining ginger (N = 4) with other ingredients were heterogeneous. Overall, combination products showed positive benefit for reducing pain and possibly overall health/quality of life but not for improving function.
| Ingredient Evaluated | Comparators | No. Studies/Participants | Populations | Outcomes | Evidence | Quality | Adverse Events | Considerations |
|----------------------|-------------|--------------------------|-------------|----------|----------|---------|---------------|----------------|
| Glucosamine Rx/OTC†  | vs varying  | 3 trials on pCGS, RottaPharm | Osteoarthritis | Pain reduction | SMD (3 trials) = \( -0.27, 6.75 \) pts greater reduction than comparator | Moderate | Although may cause nausea, heartburn, diarrhea, constipation, drowsiness, skin reaction or headache, glucosamine sulfate at 1,500 mg/d is tolerated at least as well as 1,200 mg/d of ibuprofen. |
|                      |             |                          |             |          |          |         | • Moderate-quality evidence supports the use of glucosamine in the form of pCGS at 1,500 mg/d and suggests that it has similar effects to ibuprofen but takes longer to obtain a response. |
|                      |             |                          |             |          |          |         | • Effects of pCGS combined with prescription chondroitin are still unknown. |
|                      |             |                          |             |          |          |         | • pCGS implementation requires obtaining a supplement with the same purity levels of the pCGS ingredients. |
|                      |             |                          |             |          |          |         | • OTC appears safe, but types and effects of formulations are unknown. |
|                      |             |                          |             |          |          |         | • Consider OTC dosage and interference with other products. |
|                      |             |                          |             |          |          |         | • Melatonin is broadly used, accepted, and available in Rx and OTC versions as a sleep aid. It may also help with combating pain, although the research is yet of low-quality evidence. |
|                      |             |                          |             |          |          |         | • Although available as 10 mg capsules, lower doses of 3–5 mg/d are only recommend until more and higher-quality evidence is available and long-term effects are known. |

Melatonin§

3–10 mg/d over 4–8 wk vs placebo 1/32 Myofascial temporo-mandibular disorder Pain Sleep \( P < 0.05 \) \( P < 0.05 \) Insufficient data to determine the quality of evidence No studies reported on AEs; non-RCTs report that side effects (e.g., drowsiness, headache, dizziness, nausea) are uncommon. Risk to experience any AE: vs placebo: insufficient data vs drug: insufficient data

vs other 2/141 Fibromyalgia Two studies showed that melatonin was effective, and in some cases more effective, than other comparators in improving pain, sleep, health-related quality of life, mood, and physical function.
| Ingredient Evaluated | Comparators | No. Studies/Participants | Populations | Outcomes | Evidence | Quality | Adverse Events | Considerations |
|----------------------|-------------|--------------------------|-------------|----------|----------|---------|---------------|----------------|
| PUFA† 300–9,600 mg/d over 4–48 wk; 1–2 g/d noted as most effective | vs any comparator | 46/2,873 | Rheumatoid arthritis, osteoarthritis, myalgia, other MSK conditions | Pain reduction | SMD (46 trials) = –0.40, 10 pts greater reduction than comparator Subgroup analyses: Omega-3 only, SMD = –0.47 Low (i.e., ≤1.35 g/d) PUFA dose, SMD = –0.55 | Moderate | Fishy aftertaste, halitosis, heartburn dyspepsia, nausea, loose stools, and rash, though generally well tolerated at doses of 3–4 g/d; higher doses associated with increased risk of bleeding and stroke. Risk to experience any AE: vs placebo: insufficient data vs drug: insufficient data | • Available in food; should be considered as a dietary source. • Nutrition education is important to ensure proper amounts of PUFA are being obtained via diet and/or supplementation to avoid possible overdose. • Increase understanding on best formulation (e.g., Omega 3/6 ratios). • Low-quality evidence suggests that vitamin D reduces pain. Recommended at doses of 2,000 IU/d, not to exceed 4,000 IU/d. • Can be obtained via food and sun exposure, but Special Operators should not solely depend on these sources due to potential lack of exposure. • Concern for potential overdose; recommend low doses until further research is conducted. |
| Vitamin D‡ 400–300,000 IU/d over anywhere from a single dose to 2 mo –2 y vs placebo¶ | 11/1,442 | Fibromyalgia, low back pain, MSK pain, osteoarthritis, rheumatoid arthritis | Pain reduction | SMD (8 trials) = –0.55, 13.75 pts greater reduction than placebo | Low | Infrequent AEs; concern that higher vitamin D doses are associated with more AEs. Risk to experience any AE: vs placebo: insufficient data vs drug: insufficient data | |

AE = adverse event; ASU = avocado soybean unsaponifiables; CI = confidence interval; MSK = musculoskeletal; NS = nonsignificant; OR = odds ratio; OTC = over-the-counter; pCGS = prescription patented Crystalized Glucosamine Sulfate; PUFA = polyunsaturated fatty acids; RCT = randomized controlled trial; RD = risk difference; SMD = standardized mean difference.

†Data from existing meta-analysis used.
‡New meta-analysis conducted.
§No meta-analysis conducted.
¶Includes data from multiple arms (placebo and other comparators).
| Ingredient       | Total Votes in Favor/Total Possible Votes | Effect Size for Pain Reduction/Quality | Certainty of the Evidence Across all Outcomes | Desirable Effects | Justification of Resource Requirements | Acceptable to Stakeholders | Feasible/Suitable to Implement | Decision |
|------------------|------------------------------------------|--------------------------------------|---------------------------------------------|-------------------|----------------------------------------|---------------------------|-------------------------------|----------|
| Curcuma†         | SMD = -1.05                               | 3 5 0 0 0                            | 0 0 2 6 0                                   | In favor = 6      | 0 1 1 6 0                              | In favor = 8               | 0 2 1 5 0                     | 75% weak, in favor |
|                  |                                           | Low                                 | VL LNS M H                                 | N PN DK PY Y      | N PN DK PY Y                           | N PN DK PY Y              | In favor = 8                   | 12.5% none |
| Glucosamine (Rx)| SMD = -0.27                               | 0 0 0 8 0                            | 0 0 2 6 0                                   | In favor = 6      | 0 0 5 3                                | In favor = 8               | 0 0 6 2                       | 37.5% weak, in favor |
|                  |                                           | Moderate                            | VL LNS M H                                 | N PN DK PY Y      | N PN DK PY Y                           | N PN DK PY Y              | In favor = 8                   | 12.5% none |
| PUFA             | SMD = -0.40                               | 0 2 0 6 0                            | 0 0 0 4 4                                   | In favor = 6      | 0 0 0 4                                | In favor = 8               | 0 0 0 5 3                     | 50% weak, in favor |
| Melatonin        | Insufficient data                         | 2 5 1 0 0                            | 0 0 3 5 0                                   | In favor = 6      | 0 2 2 4 0                              | 0 1 1 6 0                 | 0 1 0 6 1                     | 75% weak, in favor |
| Vitamin D        | SMD = -0.55                               | 0 8 0 0 0                            | 0 3 0 5 0                                   | In favor = 0      | 0 1 0 7 0                              | 1 0 1 6 0                 | 1 0 0 7 0                     | 100% weak, in favor |

ASU = avocado soybean unsaponifiables; DK = do not know; H = high; L = low; M = moderate; N = no; NS = no included studies; PN = probably no; PUFA = polyunsaturated fatty acids; PY = probably yes; RX = prescription; VL = very low; Y = yes.

*Eight voting members judged factors to consider together to develop recommendations. A summary weight is provided for each ingredient ranking the desirable consequences to the unknown or undesirable consequences across factors, which was done anonymously. The quality was not assigned a weight, as this was used to determine the weight of the certainty of the evidence across all outcomes assessed, and as supplied by the evidence review independently [Supplementary Data: Summary Report]. Although the accumulated judgments of all factors were used to inform the recommendations ultimately made and displayed using the GRADE Grid [Supplementary Data: GRADE Grid] visually, they were not assigned a weighted summary score.

†Conditionally recommend use as a food source, not as a dietary supplement, at this time.
example, Piascledine 300 is made in France, and therefore the required resources are perhaps higher than other dietary ingredients. Because it is unknown what formulations might be beneficial beyond Piascledine 300, members had divergent opinions regarding ASU’s required resources, acceptability to stakeholders, and feasibility of implementation.

Given that the desirable effects outweigh the undesirable, research should focus on understanding OTC formulations and conducting third-party evaluations before strong recommendations can be made. The purity of ASU ingredients should also be confirmed via United States Pharmacopeia (USP)–verified or NSF-certified products.

Capsaicin

Capsaicin, one of the primary constituents of the Capsicum species, is an active component of chili peppers. Capsicum is grown worldwide and adds color, pungency (i.e., heat), and aroma to food. Capsaicin is used orally, topically, and intranasally for a variety of conditions. It is most commonly used topically for MSK conditions such as osteoarthritis, rheumatoid arthritis, neuralgias/neuropathies, back pain, fibromyalgia, and muscle spasms [88]. In fact, both low-concentration OTC and Food and Drug Administration (FDA)–approved, high-concentration (i.e., Qutenza™) topical formulations are available.

Ten randomized controlled trials (RCTs) [31–40] compared the effect of capsaicin with placebo, usual treatment, or other capsaicin products within a variety of populations, including those with osteoarthritis, rheumatoid arthritis, and other MSK conditions. Capsaicin was delivered topically either as a patch or gel/cream; capsaicin gels/creams were labeled as Capsika gel®, Zostrix®, Dolarac™, Finalgon®, or Sensedol®. Daily dosages of patches containing either 0.1% or 22–37.4 μg/cm² of capsaicin were applied at times ranging from four to 12 hours over three to four weeks, whereas dosages of creams containing 0.0125–0.25% capsaicin were applied at times ranging from twice to four times daily for three to 12 weeks (Table 2; Supplementary Data: Summary Report).

Conditional recommendations were made (75% weak in favor; 12.5% none; 12.5% weak, against) for the use of curcuma as a food source in daily diets at dose equivalents of 500 mg two to three times per day for pain and related symptoms. The HERB did not recommend curcuma as a dietary supplement at this time.

A large (SMD = −1.05) and statistically significant desirable anticipated effect was noted for pain reduction, enhanced global function (SMD = −0.87), and reduced medication use (RD = −0.50), as compared with placebo at the time point closest to two months. The quality and certainty of the evidence are very low to low. Potential risk of bias across the pooled studies, small sample size, and statistically significant heterogeneity were reasons for downgrading (Supplementary Data: Summary Report).

Curcuma

Turmeric, commonly referred to by its Latin name, curcuma, is a plant related to ginger and is grown throughout India, parts of Asia, and Central America [89]. Curcuma is formulated into capsules, tablets, teas, extracts, and/or pastes and is used for inflammation, arthritis, stomach, skin, liver and gallbladder problems, cancer, and other conditions [90]. Turmeric root and powder are available as grocery items for cooking.

The authors identified 10 RCTs [42–51] meeting the review’s inclusion criteria. Studies compared curcuma, either alone (N = 7) or combined with other ingredients (N = 3), with other dietary ingredients, NSAIDs, or placebo in samples with osteoarthritis and/or rheumatoid arthritis. Doses ranged from 700 to 2,000 mg/d over 42 days to 12 weeks (Table 2; Supplementary Data: Summary Report).

Conditional recommendations were made (75% weak in favor; 12.5% none; 12.5% weak, against) for the use of curcuma as a food source in daily diets at dose equivalents of 500 mg two to three times per day for pain and related symptoms. The HERB did not recommend curcuma as a dietary supplement at this time.

A large (SMD = −1.05) and statistically significant desirable anticipated effect was noted for pain reduction, enhanced global function (SMD = −0.87), and reduced medication use (RD = −0.50), as compared with placebo at the time point closest to two months. The quality and certainty of the evidence are very low to low. Potential risk of bias across the pooled studies, small sample size, and statistically significant heterogeneity were reasons for downgrading (Supplementary Data: Summary Report).

Curcuma was rated as a high priority research area given that its potential desirable effects outweigh the minimal undesirable effects (e.g., minor gastrointestinal complaints). Until further research is conducted, curcuma is suggested as a useful dietary source but should not be used as a dietary supplement. Costs were rated as negligible to even moderate savings. There was some disagreement as to whether curcuma would be acceptable to...
stakeholders or feasible to implement. Once further research emerges, additional stakeholder debate would be required [13].

Ginger
Ginger is a tropical plant widely used as a flavoring or fragrance in foods, beverages, soaps, and cosmetics. Common forms include the fresh or dried root, tablets, capsules, liquid extracts, and teas. Ginger is currently used as a dietary ingredient for nausea, rheumatoid arthritis, and osteoarthritis [91].

Ten RCTs [52–61] met the review’s eligibility criteria, five of which were also included in Bartels et al.’s 2015 systematic review and meta-analysis [62] on ginger for osteoarthritis. Studies compared ginger, either alone or combined with other ingredients, with herbal, pharmacologic, and placebo comparators in osteoarthritis, rheumatoid arthritis, and chronic joint pain populations. Dosages ranged from 250 to 1,000 mg/d (delivered as a capsule) and 6 g/d (delivered as an ointment) over anywhere from three to 12 weeks (Table 2; Supplementary Data: Summary Report).

Whereas no recommendation was provided (37.5% weak, in favor; 37.5% none; 25% weak, against) for the use of ginger as a dietary supplement, members agreed that minimal adverse events have been noted and that the certainty and quality of the evidence for a small yet statistically significant reduction in pain (SMD = –0.30) and disability (SMD = –0.22) were moderate (Supplementary Data: Summary Report) [12,62]. The desirable anticipated effect was not as substantial as the other ingredients reported here; however, members agreed that it is already available in tea and food and, if readily available, could be suggested for use.

Although the critical threshold for a clinically relevant effect is debatable, the effect size of ginger does fall within the range of some other nutraceuticals/herbal medicines, and NSAIDs and may be beneficial to some individuals [62]. The exact dose is not well established, but plausible dose responses associated with ginger in higher doses (i.e., 1,000 mg) appear to produce a larger effect than lower doses (i.e., 250 mg) [62]. Risk of bias was detected across some studies evaluated. The cost appears negligible or even a moderate savings compared with other active ingredients for pain relief. Moreover, they concurred that it would likely justify out-of-pocket expenses and be both acceptable to stakeholders and feasible/suitable to implement, provided that any implemented supplement had the same purity levels as the pCGS ingredients, as in the RottaPharm product.

Controversy surrounds the reported effectiveness of glucosamine [94]; however, a Cochrane review recently confirmed that a particular glucosamine sulfate product (Dona, Rotta Pharmaceuticals), as opposed to other formulations, was effective in reducing osteoarthritis pain [95].

Conditional recommendations were made (62.5% weak; 37.5% strong, in favor) for the use of prescription patented Crystalized Glucosamine Sulfate (pCGS) at daily doses of 1,500 mg for pain and related symptoms. It is important to note that the controversy concerning the use of glucosamine sulfate and combination products containing glucosamine largely reflects the differing regulatory status, labeling, and availability of medications in separate countries and regions of the world. Hence, to date it appears that pCGS, as supplied by RottaPharm, is the only product with a well-documented pharmacological effect [64,95].

There is moderate overall quality and certainty that this product will produce a statistically significant effect in reducing pain (SMD = –0.27) compared with placebo [64,68]. pCGS appears to be well-tolerated, as associated undesirable effects (e.g., mild gastrointestinal complaints) are small to trivial. Although pCGS shows similar effects to ibuprofen, it does take longer to obtain a response. Members mostly agreed that the cost would be negligible to even a moderate savings compared with other active ingredients for pain relief. Moreover, they concurred that it would likely justify out-of-pocket expenses and be both acceptable to stakeholders and feasible/suitable to implement, provided that any implemented supplement had the same purity levels as the pCGS ingredients, as in the RottaPharm product.

Effects of pCGS combined with chondroitin remain unknown. OTC glucosamine is available, and although the certainty of the evidence was very low to low and the desirable effects likely small, the members believed that the undesirable effects would be small to trivial. Conditional recommendations were provided for OTC glucosamine (62.5% weak, in favor; 37.5% none), should pCGS not be available to a Special Operator.

Glucosamine, Prescription/Over-the-Counter
Glucosamine is an amino sugar naturally produced in the human body. It is required for the synthesis of glucoproteins, glycolipids, and glucosaminoglycans found in the tendons, ligaments, cartilage, synovial fluid, mucous membranes, eye structures, blood vessels, and heart valves [86]. It can also be derived from marine exoskeletons or produced synthetically [92,93]. Glucosamine sulfate and glucosamine hydrochloride are delivered orally for many MSK conditions such as temporomandibular disorder, joint pain, osteoarthritis, knee pain, and back pain. Both are also commonly combined with each other or other products (e.g., chondroitin sulfate, N-acetyl glucosamine).

Conditional recommendations were made (62.5% weak; 37.5% strong, in favor) for the use of prescription patented Crystalized Glucosamine Sulfate (pCGS) at daily doses of 1,500 mg for pain and related symptoms. It is important to note that the controversy concerning the use of glucosamine sulfate and combination products containing glucosamine largely reflects the differing regulatory status, labeling, and availability of medications in separate countries and regions of the world. Hence, to date it appears that pCGS, as supplied by RottaPharm, is the only product with a well-documented pharmacological effect [64,95].

There is moderate overall quality and certainty that this product will produce a statistically significant effect in reducing pain (SMD = –0.27) compared with placebo [64,68]. pCGS appears to be well-tolerated, as associated undesirable effects (e.g., mild gastrointestinal complaints) are small to trivial. Although pCGS shows similar effects to ibuprofen, it does take longer to obtain a response. Members mostly agreed that the cost would be negligible to even a moderate savings compared with other active ingredients for pain relief. Moreover, they concurred that it would likely justify out-of-pocket expenses and be both acceptable to stakeholders and feasible/suitable to implement, provided that any implemented supplement had the same purity levels as the pCGS ingredients, as in the RottaPharm product.

Effects of pCGS combined with chondroitin remain unknown. OTC glucosamine is available, and although the certainty of the evidence was very low to low and the desirable effects likely small, the members believed that the undesirable effects would be small to trivial. Conditional recommendations were provided for OTC glucosamine (62.5% weak, in favor; 37.5% none), should pCGS not be available to a Special Operator.

Melatonin
Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone naturally produced by the pineal gland in the brain [96]. This hormone plays a role in sleep, with production and release related to time of day (i.e., rising in
the evening, falling in the morning) [97]. Melatonin is commonly administered orally via capsule for sleep disorders but may be also used to manage neuropathies, headaches, cancers, or osteoporosis [98].

Three RCTs meeting the review’s inclusion criteria compared the effect of melatonin with either a placebo [71] or a pharmacological drug (i.e., fluoxetine [70] or amitriptyline [69]) in fibromyalgia [69,70] and myofascial temporomandibular disorder (TMJ) populations [71]. Melatonin doses ranged from 3 to 10 mg/d across four to eight weeks [71]. Baseline levels of melatonin were not reported by any study (Table 2; Supplementary Data: Summary Report).

Conditional recommendations were made (75% weak, in favor; 12.5% none; 12.5% weak, against) for short-term use of low-dose (i.e., 3–5 mg/d) USP-verified or NSF-certified melatonin products as a dietary supplement for pain and related symptoms.

Preliminary evidence demonstrates that melatonin is superior to placebo [71], and perhaps to amitriptyline [69], in reducing pain and reliance on other medications while improving sleep patterns. Little is known about how large these desirable anticipated effects may be or the potential adverse events that might be associated with long-term use. Nonrandomized trials have reported that drowsiness, headache, dizziness, and nausea are uncommon [96]. The HERB agreed that higher doses of melatonin should be avoided until further long-term studies are conducted. Melatonin is a dietary ingredient already broadly used, acceptable to many stakeholders, and available as a sleep aid, so it is likely feasible to implement for pain and sleep improvement. Associated costs are viewed as negligible or even a moderate savings compared with other pain-relieving medications. The quality and certainty of the evidence were judged to be very low to low, with insufficient studies to conduct a meta-analysis.

Polysaturated Fatty Acids
Fish oil comes from various species, including mackerel, herring, tuna, halibut, salmon, cod liver, and whale and seal blubber [99]. Thus, these types of fish are dietary sources of omega-3 fatty acids, also known as n-3 fatty acids [100]. Omega-3 fatty acids are essential dietary ingredients and include alpha-linolenic acid (ALA), long-chain omega-3 fatty acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Fish oil supplements contain varying amounts of EPA and DHA (18–51% and 12–32%, respectively) [101]. Although ALA is mainly found in green vegetables, canola oil, and soybeans, EPA and DHA almost exclusively come from fish oil and other seafood. ALA, EPA, and DHA are types of omega-3 fatty acids but may serve different functional roles and should subsequently not be considered interchangeable. Although proprietary prescription fish oil is FDA-approved to lower levels of triglycerides, nonprescription formulations of fish oil are also used for other conditions including chronic fatigue syndrome, cognitive function/impairment, and MSK (e.g., rheumatoid arthritis, muscle strength, muscle soreness, osteoporosis, osteoarthritis, migraines) issues [102].

The authors relied upon evidence on PUFA for chronic pain presented in Prego-Dominguez et al.’s 2016 systematic review and meta-analysis [72]. The majority of examined studies compared various combinations of PUFA with placebo or other comparators for pain reduction in rheumatoid arthritis patients, with doses ranging from 300 to 9,600 mg for anywhere from four to 48 weeks (Table 2; Supplementary Data: Summary Report).

Conditional recommendations were made (50% weak; 50% strong, in favor) for the use of PUFA supplementation for pain and related symptoms, incorporated into the daily diet at 1,200 mg/d, and not to exceed 2 g/d. Whereas the undesirable effects appear to be small to trivial at low doses, >3 g/d is likely to increase the potential for adverse events (e.g., inhibition of platelet aggregation, risk of bleeding, and potentially hemorrhagic stroke at very high doses) (Supplementary Data: Summary Report).

Moderate-quality evidence suggests that the desirable anticipated effects for pain reduction (SMD = −0.40 range) are statistically significant as compared with placebo [72]. Heterogeneity is noted across the assessed studies and is likely due to varying blends of omega-3/6 used. Although research points to the association between omega-3, rather than omega-6, and pain reduction, the exact ratio, dose, and duration of PUFA use are yet to be determined; most studies, however, report benefit between 1 and 2 g/d. PUFA do have preventive benefits, are available in food, and should be considered as a dietary source. Nutrition education is critical, moreover, to ensure that the proper amounts are being obtained via food or supplementation to avoid excessive intake. Members mostly agreed that the certainty of the evidence is moderate and that cost is negligible, with even moderate savings compared with currently used pain medications. Subsequently, PUFA are likely acceptable, feasible, and suitable to implement as a dietary food source or supplement, preferably from a USP-verified or NSF-certified product.

Vitamin D
Vitamin D is a fat-soluble vitamin obtained from sun exposure, food, and/or dietary supplements. Vitamin D promotes calcium absorption, is necessary for bone growth, and appears to also affect skeletal muscle, immune regulation, cardiovascular health, and metabolic activities [103]. Vitamin D deficiencies can result in thin, brittle, or misshapen bones, bone pain, muscle weakness, rickets, and osteomalacia [104–106]. Vitamin D is most commonly used for osteoporosis, osteomalacia, and falls
and fractures in individuals at risk for osteoporosis [107]

The authors relied on the systematic review published by Wu et al. [85] and individual RCTs examining populations with rheumatoid arthritis, chronic low back, fibromyalgia, chronic nonspecific MSK pain, and knee osteoarthritis [73–84] to evaluate and present the evidence on vitamin D for chronic MSK pain. Ingredients were labeled calcifediol [73,75], vitamin D2 [74,77], vitamin D3 [76,78,79,81–83], and vitamin D [84]. Baseline vitamin D levels ranged from 12.8 ± 8.7 to 42.9 ± 11.3 ng/mL in the vitamin D group and 15.0 ± 3.0 to 37.3 ± 13.2 ng/mL in the comparator arm. Dosages ranged from 400 IU to 300,000 IU/d for anywhere from a single dose to a course of two years. All studies except one [76] that included a triglyceride solution compared vitamin D with placebo (Table 2; Supplementary Data: Summary Report).

Following a strict methodological approach and using evidence to guide judgments [13], conditional recommendations (100% weak, in favor) were made for the use of vitamin D supplementation for pain and related symptoms at doses of 2,000 IU/d, not to exceed 4000 IU/d. Higher doses should only be used for short-term treatment of vitamin D deficiency and when instructed by a health care provider. Recent evidence suggests that individuals who consume high doses of vitamin D could be at risk of vitamin D intoxication, dysregulation of calcium and phosphorous metabolism, hypercalcemia, hypercalciuria, and hyperphosphatemia. Current approaches to assessing serum levels of 25 hydroxyvitamin D do not necessarily reflect current intake or stores of vitamin D [103,108].

Based on the evidence, the HERB judged the desirable anticipated effects for pain reduction to be moderate in size (SMD = −0.55) at final follow-up, and results were statistically significant compared with placebo when used at low doses [85]. Undesirable effects were judged to be small to trivial. This research is of low quality, primarily due to concerns over heterogeneity, varying populations with potentially different baseline vitamin D levels, and varying doses and durations of intake, which make interpretation challenging (Supplementary Data: Summary Report). Members judged the certainty of the evidence to be low and agreed that cost was negligible compared with ibuprofen 2400 mg/d.

Because the desirable effects likely outweigh the undesirable, resource requirements may justify vitamin D use. Members agreed that vitamin D up to 2,000 IU per day would probably be feasible and acceptable to stakeholders when the product was produced by reputable manufacturers and sold by trusted vendors. Only some vitamin D products sold are on the United States Pharmacopeia National Formulary (USP-NF) verified product list [109]. Although vitamin D can be obtained via food and sun exposure, the HERB members agreed that Special Operators may not receive adequate exposure to sunlight due to wearing long-sleeved clothing/tactical gear and being outside during nighttime operations.

**Discussion**

Evidence-based conditional recommendations have been made for various dietary ingredients, which suggests that they could be used in support of managing chronic MSK pain, specifically for Special Operations Forces (SOF). Nineteen dietary ingredients (Figure 1) had sufficient scientific evidence available to evaluate the state-of-the-science and evidence for any desirable and undesirable anticipated effects on chronic MSK pain, function, and related outcomes through systematic review and meta-analysis techniques. The GRADE approach was used to determine the quality of that evidence by examining the risk of bias, inconsistency, imprecision, and indirectness from the pooled studies. Subject matter experts and key stakeholders evaluated the certainty of the overall evidence, weighed the desirable to undesirable anticipated effects, and considered resource requirements, acceptability, and feasibility/suitability to determine the strength and direction of evidence-based recommendations that could be practical/useful to SOF (Table 3).

ASU, capsaicin, curcuma, ginger, glucosamine, melatonin, PUFA, and vitamin D are recommended and may help alleviate chronic MSK pain. They are suggested for use when taken either as part of a balanced diet and/or as a supplement or applied as a cream. Individuals should discuss options with a health care provider before initiating use of any dietary ingredient. Individuals should also select USP-verified products when possible as they 1) contain the ingredients listed on the label in the declared potency and amounts, 2) contain no harmful levels of specified contaminants, 3) break down and release into the body within a specified amount of time, and 4) have been made according to FDA current Good Manufacturing Practices by using sanitary and well-controlled procedures [110]. Operators can also consider NSF Certified for Sport [111] products and refer to Operation Supplement Safety, a Department of Defense dietary supplement resource [112,113], to verify safety.

Because recommendations were only conditional and did not strongly endorse an ingredient for immediate use, discussion and debate among stakeholders before policy decisions are made surrounding these dietary ingredients and future efforts worthy of further investigation are encouraged.

**Weighing the Desirable and Undesirable Effects**

The HERB members weighed desirable and undesirable anticipated effects based on the evidence supplied through systematic review and meta-analysis. Each conditionally recommended ingredient showed an improvement in pain over time compared with placebo or other active comparators. The quality of that evidence varied more than several times.
among the dietary ingredients evaluated. For example, evidence for pain reduction via capsaicin and PUFA is high and moderate, respectively; conversely, the evidence that vitamin D will produce a statistically significant reduction in pain associated with chronic MSK pain is of low quality. Further, although curcuma shows the largest estimated effect for decreasing pain and improving global function, and perhaps decreasing medication use, the quality of the evidence is very low to low. Some ingredients showed improvement in other pain-related outcomes, but how these ingredients affect such outcomes overall and whether they influence outcomes beyond those in Table 2 are unknown.

In addition, how substantial these reported desirable effects might be for any one individual may vary significantly. What is considered a clinically meaningful improvement in pain, as well as other outcomes, is under considerable debate and is a point of discussion by the HERB members. Bartels et al., in 2010 [114], compared the SMD from their meta-analysis with other SMDs noted from other interventions, stating,

The SMD of 0.30 for ginger compared with placebo correspondsto an effect size for pain which is only slightly above the critical threshold limit for a relevant SMD in osteoarthritis [115], and it is comparable, although a little higher, to the SMD of 0.21 seen with intake of acetaminophen [116]. The observed pain reducing effect for ginger is in the same range as SMD previously reported for other nutraceutical/herbal medicines like diacerein with an SMD of 0.24 [114], ASU with an SMD of 0.39 [114], and rose hip powder of 0.37 [117], all in comparison with placebo. Compared to the effect of NSAIDs, the SMD for ginger has an effect size in the middle of the NSAID range of 0.17 to 0.66, all when compared to placebo [118–120].

The HERB used the effect of high-dose ibuprofen, 2,400 mg/d, reported as SMD = −0.41 compared with placebo [118], as a reference point. To date, comparative effectiveness trials across dietary ingredients are heterogeneous and challenging to pool in meta-analysis in any meaningful way. Further research is needed for comparing ingredients with placebo and other standards of care.

Undesirable anticipated effects, as reported in the evaluated studies, primarily consisted of minor gastrointestinal complaints. Given their nonserious and infrequent nature, members judged that the desirable effects outweighed the undesired across all dietary ingredients. Currently data from published studies showing how these ingredients directly compare with other active comparators in terms of varying adverse events are insufficient. There is concern that when used at higher doses, more and additional adverse events, beyond gastrointestinal issues, may occur. For example, extremely high doses of PUFA may increase the risk of both ischemic and hemorrhagic stroke [121], and extremely high doses of vitamin D could lead to intoxication [122]. Other adverse events, though relatively mild (e.g., “bad taste” associated with ginger and PUFA) can cause some individuals to discontinue use [62,123,124].

Certainty of the Evidence
Although the quality of the evidence was determined using the GRADE approach and was specific to each outcome evaluated, the certainty of the evidence was judged based on reviewing the evidence of effects across all outcomes where it was feasible to pool results into a meta-analysis (Table 2; Supplementary Data: Summary Report.) Members judged the certainty of the overall evidence for PUFA and ginger as moderate and for curcuma and vitamin D as very low to low. Further research is needed to address gaps of ingredients with low-quality studies and uncertain evidence. In some circumstances, the use of ingredients with some evidence suggesting desirable effect can be suggested when the risk of using the ingredient is minimal. In all cases, discussions with a health care provider are recommended to consider ingredient use and an approach to shared decision-making.

Justification of Resource Requirements/Cost
Cost is an essential factor required for decision-making that affects all individuals at some level. On average, given the doses reported in the studies, the cost associated with any of these ingredients was considered negligible to moderate savings compared with commonly used pain relievers (e.g., ibuprofen 2,400 mg, estimated at approximately $1/d to serve as a reference point for comparison). As such, most members agreed that resource requirements and out-of-pocket costs were justified.

Other Considerations: Feasibility, Acceptability, Suitability
The HERB members agreed that capsaicin, pCGS, melatonin, PUFA, and vitamin D would probably be acceptable to stakeholders and feasible/suitable to implement as a policy of practice, whereas there was more debate concerning ginger, curcuma, and ASU. Although ginger and curcuma should both be considered a dietary food (e.g., teas, cooking ingredient) and may have the potential to preemptively mitigate pain, there was insufficient strong research for recommending their use as a supplement. The overall effect of ginger was relatively small, and although curcuma produced a large effect, the authors were less confident in that effect estimate. It is possible that these ingredients could be inserted into a mission planning process and added to a nutrition checklist by mission dietitians. Whether it would be feasible for Special Operators to obtain ginger and curcuma during specific operational missions is unknown.

Research on ASU evaluated by the authors was confined to the commercialized French product Piascledine. The quality of the evidence for its effects on pain reduction is moderate, diminished by potential bias of being
funded by the manufacturer. Third-party evaluations of Piascledine are needed. In addition, Piascledine 300 costs more than the other dietary ingredients and other products that claim to be made with ASU. HERB members agreed regarding Piascledine or other ASU products’ (that lack rigorous clinical evidence) acceptability and feasibility were diverse.

Remarks on the Methodological Approach
Systematic reviews provide essential information to lay the foundation for evidence-based practice but are often insufficient for making well-informed decisions. Stakeholders can easily judge the appropriateness of an intervention or treatment when high-quality evidence supports substantial desirable anticipated effects and there are minimal to no undesirable anticipated effects. In these cases, treatments are recommended with little need for further debate. Little debate is needed when treatments are judged to be inappropriate and risks clearly outweigh benefits. In between these two judgments is a massive gray area where the evidence is of low, indeterminate, or equivocal quality. Importantly, dietary ingredients are not intended to treat any particular health condition. If a particular ingredient or combination of ingredients were identified as potentially useful for mitigating or treating MSK pain, then the ingredient would be classified as a drug and required to go through the FDA Investigational New Drug Applications process [125]. Despite this, many dietary supplements are marketed for pain relief. A casual search of the National Institutes of Health’s Office of Dietary Supplement’s Dietary Supplement Label Database (https://www.dsld.nlm.nih.gov/dsld/index.jsp) yielded a total of 272 products when the terms “pain” and “muscle” were used to search for label statements or health claims. Thus, caution is urged, and obtaining ingredients through food is always preferred, unless the evidence of safety and efficacy is clear and manufacturers’ production processes are verified or certified by trusted third parties.

A framework for decision-making is essential. The authors involved diverse subject matter experts and key stakeholders proactively to develop key questions and to drive the direction of evidence evaluation that illuminated critical outcomes and factors important to them. This evaluation, conducted by a third party, used processes and procedures designed to minimize bias. Factors required for decision-making for this project were adapted from the GRADE framework and specific to the Special Operations environment. The integration of systematic review results into the GRADE Evidence to Decision Framework and the use of a modified Delphi voting process seeking points of convergence and divergence enable all voices to be heard. Subsequently, recommendations about practice, policy, and next steps for research that are useful to the diversity of end users can be developed. A limitation in all research is wide generalizability, and the framework used here can be adapted to different contexts, settings, and stakeholders to consider other essential factors important for decision-making.

Conclusions
Conditional, evidence-based recommendations were made for the use of vitamin D (2,000 mg/d), PUFA (1,200 mg/d), curcuma and ginger (as food sources), melatonin (3–5 mg/d), a proprietary brand of ASU (300–600 mg/d), capsaicin (as a cream, 0.025–0.075% applied 3–4/d), and prescription glucosamine (pCGS, 1,500 mg/d) as alternative or supplemental approaches for mitigating pain and related symptoms associated with chronic MSK pain. These recommendations were based upon rigorous evidence evaluation and integrated with expert clinical acumen by using strict methodological criteria and processes designed and practiced to minimize bias. The process allowed for all voices to be heard with regard to reaching the greatest spread of end user impact. Caveats exist, and in some cases the quality and/or certainty of the evidence remains low; however, the resulting recommendations can serve as a decision aid for practitioners and participants to make shared decisions.

Acknowledgments
The authors would like to acknowledge Lynn Teo, Charmagne F. Paat, Karin Meissner, and Cindy Lentino for their contributions to the systematic review and meta-analysis effort that informed the recommendations made.

The Holistic Evidence Review Board (HERB) consisted of the following individuals: Dr. Kevin Berry, Vice President, TLI Foundation; Dr. Robert Bonakdar, Academy of Integrative Pain Management and Director of Pain Management, Scripps Center for Integrative Medicine; SGM F. Bowling, Office of the Command Surgeon, US Special Operations Command and US Army Special Forces Medic; CAPT Scott Kota, Command Surgeon, US Special Operations Command; Dr. Rebecca Costello, Scientific Consultant, Office of Dietary Supplements, National Institutes of Health; Dr. Patricia A. Deuster, Director of the Consortium for Health and Military Performance at the Uniformed Services University (CHAMP/USU); Dr. Tonya Dodge, Associate Professor of Psychology, George Washington University; Dr. C. Douglas Forcino, Director of the US Special Operations Command Programs at CHAMP/USUHS; Dr. Travis Harvey, Program Development Manager, US Special Operations Command, Preservation of the Force and Family, Human Performance; Col (ret.) Jeffery Johnson, 88th Pharmacy Flight Commander AFMC/TeamRx Consultant 88th DTS/88th MDG/88th MDG/88th ABW/WPAFB and member of the Air Force Nutrition and Supplements Subcommittee; COL (ret.)
Steven Swann, Independent Military Medicine Consultant and former Command Surgeon, US Special Operations Command; CAPT Necia Williams, Anesthesiologist and Command Surgeon, US Marine Corps Special Operations Command.

Supplementary Data

Supplementary data are available at Pain Medicine online.

References

1. Armed Forces Health Surveillance Center. Absolute and relative morbidity burdens attributable to various illnesses and injuries, U.S. Armed Forces, 2013. MSMR 2014;21(4):2–7.
2. Bullock S, Jones B, Gilchrist J, Marshall S. Prevention of physical training-related injuries recommendations for the military and other active populations based on expedited systematic reviews. Am J Prev Med 2010;38(Suppl 1):S156–81.
3. Hauret K, Jones B, Bullock S, Canham-Chervak M, Canada S. Musculoskeletal injuries description of an under-recognized injury problem among military personnel. Am J Prev Med 2010;38(Suppl 1):S61–70.
4. Office of the Army Surgeon General, Pain Management Task Force. Pain Management Task Force Report. Office of the Army Surgeon General: Pain Management Task Force; 2010. http://www.dvcipm.org/clinical-resources/pain-management-task-force/ (accessed March 10, 2019).
5. Knapik J, Steelman R, Hoedebecke S, et al. A systematic review and meta-analysis on the prevalence of dietary supplement use by military personnel. BMC Complement Altern Med 2014;14:143. (doi: 10.1186/1472-6882-14-143).
6. Council for Responsible Nutrition. CRN 2016 Annual Survey on Dietary Supplements. Available at: https://www.crnusa.org/resources/crn-2016-annual-survey-dietary-supplements. (accessed March 10, 2019).
7. Buckenmaier C, Crawford C, Lee C, Schoomaker E. Are active self-care complementary and integrative therapies effective for management of chronic pain? A rapid evidence assessment of the literature and recommendations for the field. Pain Med 2014;15(1):1–5113.
8. Complementary Medicine Research. Journal club. Complement Med Res 2017;24:207–13.
9. De Silva V, El-Metwally A, Ernst E, Lewith G, Macfarlane GJ. Evidence for the efficacy of complementary and alternative medicines in the management of osteoarthritis: A systematic review. Rheumatology 2011;50(5):911–20.
10. National Academies of Sciences. Pain Management and Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington, DC: The National Academies Press; 2017.
11. Cota S, Williams N, Neff R, Deuster P. How Evidence-Based Recommendations May Direct Policy Decisions Regarding Appropriate Selection and Use of Dietary Ingredients for Improving Pain. Pain Med 2019;20(6):1063–5.
12. Crawford C, Boyd C, Berry K, Deuster P; HERB Working Group. Dietary Ingredients Requiring Further Research before Evidence-Based Recommendations Can be Made for their Use as an Approach to Mitigating Pain. Pain Med 2019; (doi: 10.1093/pm/pnz050).
13. Crawford C, Boyd C, Paat C, et al. Dietary Ingredients as an Alternative Approach for Mitigating Chronic Musculoskeletal Pain: Evidence-based Recommendations for Practice and Research in the Military. Pain Med 2019;20(6):1236–47.
14. Institute of Medicine. Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies Press; 2011.
15. Deyo R, Dworkin S, Amtmann D, et al. Report of the Task Force on Research Standards for chronic low-back pain. Phys Ther 2015;95(2):e1–18.
16. Centers for Disease Control and Prevention. The National Institute for Occupational Safety and Health (NIOSH) Musculoskeletal Health Program. Available at: https://www.cdc.gov/niosh/programs/msd/default.html. (accessed March 10, 2019).
17. Cleveland Clinic. Musculoskeletal pain. Available at: http://my.clevelandclinic.org/health/articles/musculoskeletal-pain. (accessed March 10, 2019).
18. United States Special Operations Command. Policy memorandum 16-29: Policy on performance enhancing substance use for Special Operations Forces. United States Special Operations Command. September 27, 2016.
19. Office of Dietary Supplements. Available at: www.ods.od.nih.gov. (accessed March 10, 2019).
20. GRADE Working Group. Grading of Recommendations Assessment, Development and Evaluation (GRADE). Available at: http://www.gradeworkinggroup.org/. (accessed March 10, 2019).
21. Coulter I, Adams A. Consensus methods, clinical guidelines, and the RAND study of chiropractic. ACA J Chiropr 1992;60–1. https://www.rand.org/pubs/external_publications/EP19920003.html (accessed March 10, 2019).
22. Coulter I, Shekelle P, Mootz R, Hansen D. The Use of Expert Panel Results: The RAND Panel for Appropriateness of Manipulation and Mobilization of the Cervical Spine. Santa Monica, CA: RAND; 1997.
23. Jaeschke R, Guyatt G, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice
Conditionally Recommended Dietary Ingredients for Pain

24. Blotman F, Maheu E, Walwik A, Caspard H, Lopez A. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rheum Engl Ed 1997;64(12):825–34.

25. Appelboom T, Schueremans J, Verbruggen G, Henrotin Y, Reginster JY. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) on joint space loss in osteoarthritis of the hip. A double blind, prospective, placebo-controlled study. Scand J Rheumatol 2001;30(4):242–7.

26. Maheu E, Cadet C, Marty M, et al. Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: The ERADIAS study. Ann Rheum Dis 2014;73(2):376–84.

27. Maheu E, Mazieres B, Valat JP, et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: A prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum 1998;41(1):81–91.

28. Pavelka K, Coste P, Geher P, Krejci G. Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clin Rheumatol 2010;29(6):659–70.

29. Lequesne M, Maheu E, Cadet C, Dreiser RL. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum 2002;47(1):50–8.

30. Scottish Intercollegiate Guidelines Network (SIGN). A guideline developer’s handbook. Available at: https://www.sign.ac.uk/checklists-and-notes.html.

31. Casanueva B, Rodero B, Quintal C, Llorca J, González-Gay MA. Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients. Rheumatol Int 2013;33(10):2665–70.

32. Cho J-H, Brodsky M, Kim E-J, et al. Efficacy of a 0.1% capsaicin hydrogel patch for myofascial neck pain: A double-blinded randomized trial. Pain Med 2012;13(7):965–70.

33. Chrubasik S, Weiser T, Beime B. Effectiveness and safety of topical capsaicin cream in the treatment of chronic soft tissue pain. PTR 2010;24(12):1877–85.

34. Frerick H, Keitel W, Kuhn U, et al. Topical treatment of chronic low back pain with a capsicum plaster. Pain 2003;106(1–2):59–64.

35. Kosuwon W, Sirichatiwapee W, Wisanuyotin T, Jeeravipoolvaram P, Laupattarakasem W. Efficacy of symptomatic control of knee osteoarthritis with 0.0125% of capsaicin versus placebo. J Med Assoc Thai 2010;93(10):1188–95.

36. Schnitzer TJ, Posner M, Lawrence ID. High strength capsaicin cream for osteoarthritis pain: Rapid onset of action and improved efficacy with twice daily dosing. J Clin Rheumatol 1995;1(5):268–73.

37. Keitel W, Frerick H, Kuhn U, et al. Capsicum pain plaster in chronic non-specific low back pain. Arzneimittel-Forschung 2001;51(11):896–903.

38. Altman RD, Aven A, Holnburg CE, et al. Capsaicin cream 0.025% as monotherapy for osteoarthritis: A double-blind study. Semin Arthritis Rheum 1994;23(6):25–33.

39. Deal CL, Schnitzer TJ, Lipstein E, et al. Treatment of arthritis with topical capsaicin: A double-blind trial. Clin Ther 1991;13(3):383–95.

40. Winocur E, Gavish A, Halachmi M, Eli I, Gazit E. Topical application of capsaicin for the treatment of localized pain in the temporomandibular joint area. J Orofac Pain 2000;14(1):31–6.

41. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004;328(7446):991. (doi:10.1136/bmj.38042.506748.EE).

42. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Physiother Res 2012;26(11):1719–25.

43. Panahi Y, Rahimnia AR, Sharafi M, et al. Curcuminoid treatment for knee osteoarthritis: A randomized double-blind placebo-controlled trial. Physiother Res 2014;28(11):1625–31.

44. Nakagawa Y, Mukai S, Yamada S, et al. Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: A randomized, double-blind, placebo-controlled prospective study. J Orthop Sci 2014;19(6):933–9.

45. Kuptniratsaikul V, Thanakkhumtorn S, Chinswangwatanakul P, Wattanamongkonsil L, Thamlikitkul V. Efficacy and safety of curcuma domestica extracts in patients with knee osteoarthritis. J Altern Complement Med 2009;15(8):891–7.

46. Madhu K, Chanda K, Saji MJ. Safety and efficacy of curcuma longa extract in the treatment of painful knee osteoarthritis: A randomized placebo-controlled trial. Inflammopharmacology 2013;21(2):129–36.

47. pinsornsak P, Niempoog S. The efficacy of Curcuma longa L. extract as an adjuvant therapy in primary knee osteoarthritis: A randomized control trial. J Med Assoc Thai 2012;95(Suppl 1):S51–8.

48. Kuptniratsaikul V, Dajpratham P, Taecharappornkul W, et al. Efficacy and safety of curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: A multicenter study. Clin Interv Aging 2014;9:451–8.
49. Kulkarni RR, Patki PS, Jog VP, Gandage SG, Patwardhan B. Treatment of osteoarthritis with a herbo-mineral formulation: A double-blind, placebo-controlled, cross-over study. J Ethnopharmacol 1991;33(1–2):91–5.

50. Kizhakkedath R. Clinical evaluation of a formulation containing curcuma longa and boswellia serrata extracts in the management of knee osteoarthritis. Mol Med Rep 2013;8(5):1542–8.

51. Badria FA, El-Farahaty T, Shabana AA, Hawas SA, El-Batoty MF. Boswellia-curticun preparation for treating knee osteoarthritis: A clinical evaluation. Altern Complement Ther 2002;8(6):341–8.

52. Zakeri Z, Izadi S, Bari Z, et al. Evaluating the effects of ginger extract on knee pain, stiffness and difficulty in patients with knee osteoarthritis. J Med Plant Res 2011;5(15):3375–9.

53. Altman RD, Marcussen KC. Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis Rheum 2001;44(11):2531–8.

54. Niempoog S, Pawa KK, Amatyakul C. The efficacy of powdered ginger in osteoarthrosis of the knee. J Med Assoc Thai 2011;94(9):515–21.

55. Wigler I, Grotto I, Caspi D, Yaron M. The effects of a specific ginger combination on symptomatic gonarthritis. Osteoarthritis Cartilage 2003;11 (11):783–9.

56. Zahmatkash M, Vafaenasab MR. Comparing analgesic effects of a topical herbal mixed medicine with salicylate in patients with knee osteoarthritis. Pak J Biol Sci 2011;14(13):715–9.

57. Bliddal H, Rosetzsky A, Schlichting P, et al. A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis Cartilage 2000;8(1):9–12.

58. Haghighi M, Khalvat A, Toliat T, Jallaei S. Comparing the effects of ginger (Zingiber officinalis) extract and ibuprofen on patients with osteoarthritis. Arch Iran Med 2005;8(4):267–71.

59. Drozdov VN, Kim VA, Tkachenko EV, Varvanina GG. Influence of a specific ginger combination on gastropathy conditions in patients with osteoarthritis of the knee or hip. J Altern Complement Med 2012;18(6):583–8.

60. Chopra A, Saluja M, Tillu G, et al. Comparable efficacy of standardized ayurveda formulation and hydroxyclooroquine sulfate (HCQS) in the treatment of rheumatoid arthritis (RA): A randomized investigator-blind controlled study. Clin Rheumatol 2012;31(2):259–69.

61. Nieman DC, Shanely RA, Luo B, et al. A commercialized dietary supplement alleviates joint pain in community adults: A double-blind, placebo-controlled community trial. Nutr J 2013;12(1):154. (doi:10.1186/1475-2891-12-154).

62. Bartels EM, Folmer VN, Bliddal H, et al. Efficacy and safety of ginger in osteoarthritis patients: A meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage 2015;23(1):13–21.

63. Bruyere O, Pavelka K, Rovati L, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: Results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage 2008;16(2):254–60.

64. Eriksen P, Bartels E, Altman R, et al. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: A meta-analysis of placebo-controlled trial. Arthritis Care Res 2014;66 (12):1844–55.

65. Kongtharvonskul J, Anothaisintawee T, McEvoy M, et al. Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: A systematic review and network meta-analysis. Eur J Med Res 2015;20:24. (doi:10.1186/s40001-015-0115-7).

66. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2009;2:CD002946.

67. Zeng C, Wei J, Li H, et al. Effectiveness and safety of glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee. Sci Rep 2015;5:16827. (doi:10.1038/srep16827).

68. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: Part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010;18(4):476–99.

69. de Zanette SA, Vercelino R, Laste G, et al. Melatonin analogues is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: A phase II, randomized, double-dummy, controlled trial. BMC Pharmacol Toxicol 2014; 15:40. (doi:10.1186/2050-6511-15-40).

70. Hussain SA, Al K, II, Jasim NA, Gorial FI. Adjutant use of melatonin for treatment of fibromyalgia. J Pineal Res 2011;50(3):267–71.

71. Vidor LP, Torres IL, Custodio de Souza IC, Fregni F, Caumo W. Analgesic and sedative effects of melatonin in temporomandibular disorders: A double-blind, randomized, parallel-group, placebo-controlled study. J Pain Symptom Manage 2013;46 (3):422–32.

72. Prego-Dominguez J, Hadrya F, Takkouche B. Polyunsaturated fatty acids and chronic pain: A systematic review and meta-analysis. Pain Physician 2016;19(8):521–35.

73. Salesi M, Farazjadegan Z. Efficacy of vitamin D in patients with active rheumatoid arthritis receiving methotrexate therapy. Rheumatol Int 2012;32 (7):2129–33.
74. Hansen KE, Bartels CM, Gangnon RE, Jones AN, Gogineni J. An evaluation of high-dose vitamin D for rheumatoid arthritis. J Clin Rheumatol 2014;20(2):112–4.

75. Sandoughi M, Zakeri Z, Mirhosainee Z, Mohammadi M, Shahbakhsh S. The effect of vitamin D on non-specific low back pain. Int J Rheum Dis 2015;18(8):854–8.

76. Wepner F, Scheuer R, Schuetz-Wieser B, et al. Effects of vitamin D on patients with fibromyalgia syndrome: A randomized placebo-controlled trial. Pain 2014;155(2):261–8.

77. Warner AE, Arnspiger SA. Diffuse musculoskeletal pain is not associated with low vitamin D levels or improved by treatment with vitamin D. J Clin Rheumatol 2008;14(1):12–6.

78. Gendelman O, Itzhaki D, Makarov S, Bennun M, Amital H. A randomized double-blind placebo-controlled study adding high dose vitamin D to analgesic regimens in patients with musculoskeletal pain. Lupus 2015;24(4–5):483–9.

79. McAlindon T, LaValley M, Schneider E, et al. Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: A randomized controlled trial. JAMA 2013;309(2):155–62.

80. Jin X, Jones G, Cicuttini F, et al. Effect of vitamin D supplementation on tibial cartilage volume and knee pain among patients with symptomatic knee osteoarthritis: A randomized clinical trial. JAMA 2016;315(10):1005–13.

81. Sanghi D, Mishra A, Sharma AC, et al. Does vitamin D improve osteoarthritis of the knee: A randomized controlled pilot trial. Clin Orthop Relat Res 2013;471(11):3556–62.

82. Knutsen KV, Madar AA, Brekke M, et al. Effect of vitamin D on musculoskeletal pain and headache: A randomized, double-blind, placebo-controlled trial among adult ethnic minorities in Norway. Pain 2014;155(12):2591–8.

83. Schreuder F, Bernsen RM, van der Wouden JC. Vitamin D supplementation for nonspecific musculoskeletal pain in non-Western immigrants: A randomized controlled trial. Ann Fam Med 2012;10(6):547–55.

84. Sakalli H, Arslan D, Yucel AE. The effect of oral and parenteral vitamin D supplementation in the elderly: A prospective, double-blinded, randomized, placebo-controlled study. Rheumatol Int 2012;32(8):2279–83.

85. Wu Z, Malihi Z, Stewart AW, Lawes CM, Scragg R. Effect of vitamin D supplementation on pain: A systematic review and meta-analysis. Pain Physician 2016;19(7):415–27.

86. Therapeutic Research Center. Avocado. Available at: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=890#dosing. (accessed March 10, 2019).

87. Christiansen B, Bhatti S, Goudarzi R, Emami S. Management of osteoarthritis with avocado/soybean unsaponifiables. Cartilage 2015;6(1):30–44.

88. Therapeutic Research Center. Capsicum. Available at: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=945. (accessed March 10, 2019).

89. US National Institutes of Health, National Center for Complementary and Integrative Health. Turmeric. Available at: https://nccih.nih.gov/health/turmeric/ataglance.htm. (accessed March 10, 2019).

90. US National Institutes of Health, National Center for Complementary and Integrative Health. Ginger. Available at: https://nccih.nih.gov/health/ginger. (accessed March 10, 2019).

91. Therapeutic Research Center. Glucosamine Sulfate. Available at: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=807. (accessed March 10, 2019).

92. Therapeutic Research Center. Glucosamine hydrochloride for treating osteoarthritis. Cochrane Database Syst Rev 2005;2:CD002946.

93. Fox B, Stephens M. Glucosamine hydrochloride for the treatment of osteoarthritis symptoms. Clin Interv Aging 2008;2(4):599–604.

94. Bruyere O, Altman R, Reginster J. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum 2016;45(4 Suppl):S12–7.

95. Towheed T, Maxwell L, Anastassiades T, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005;2:CD002946.

96. US National Institutes of Health, National Center for Complementary and Integrative Health. Melatonin: In depth. Available at: https://nccih.nih.gov/health/melatonin. (accessed March 10, 2019).

97. Brzezinski A. Melatonin in humans. New Engl J Med 1997;336(3):186–95.

98. Therapeutic Research Center. Available at: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=940. (accessed March 10, 2019).

99. United States Department of Agriculture (USDA). Original food guide pyramid patterns and description of USDA analyses. Addendum A: EPA and DHA content of fish species. 2004. Available at: http://www.health.gov/dietaryguidelines/dga2005/report/HTML/table_g2_adda2.htm. (accessed March 10, 2019).

100. Harper CR, Jacobson TA. Beyond the Mediterranean diet: The role of omega-3 fatty acids
in the prevention of coronary heart disease. Prev Cardiol 2003;6(3):136–46.

101. National Institutes of Health, Office of Dietary Supplements. Omega-3 fatty acids. Available at: https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/#en30. (accessed March 10, 2019).

102. Therapeutic Research Center. Fish oil. Available at: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=993. (accessed March 10, 2019).

103. Razzaque M. Can adverse effects of excessive vitamin D supplementation occur without developing hypervitaminosis D? J Steroid Biochem Mol Biol 2018;180:81–6.

104. Institute of Medicine. Food and Nutrition Board. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: The National Academy Press; 1999.

105. Holick M. Vitamin D: Importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004;79(3):362–71.

106. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academy Press; 2010.

107. Therapeutic Research Center. Vitamin D. Available at: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=929. (accessed March 10, 2019).

108. Zhao J, Zeng X, Wang J, Liu L. Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: A systematic review and meta-analysis. JAMA 2017;318(24):2466–82.

109. United States Pharmacopeia and the National Formulary. Available at: http://www.uspnf.com/.

110. United States Pharmacopeia. USP Verified Mark. Available at: http://www.usp.org/verification-services/verified-mark. (accessed March 10, 2019).

111. NSF International. NSF Certified for Sport. Available at: http://nssfspport.com/. (accessed March 10, 2019).

112. Attipoe S, Manganello C, Scott J, Deuster P. Usefulness of a risk assessment tool to risk stratify dietary supplements. Mil Med 2017;182(11/12):e2086.

113. Operation Supplement Safety. Available at: https://www.opss.org/. (accessed March 10, 2019).

114. Bartels EM, Bliddal H, Schondorf PK, et al. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: A meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage 2010;18(3):289–96.

115. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Philadelphia, PA: Lawrence Earlbaum Associates; 1988.

116. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004;63(8):901–7.

117. Christensen R, Bartels EM, Altman RD, Astrup A, Bliddal H. Does the rose hip powder of rosa canina (rosehip) reduce pain in osteoarthritis patients? A meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2008;16(9):965–72.

118. Stam W, Jansen J, Taylor S. Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: A mixed treatment comparison. Open Rheumatol J 2012;6:6–20.

119. Trijau S, Avouac J, Escalas C, Gossec L, Dougdos M. Influence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: A meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage 2010;18(8):1012–8.

120. Bjordal JM, Ljunggren AE, Klovning A, Slordal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: Meta-analysis of randomised placebo controlled trials. BMJ 2004;329(7478):1317. (doi:10.1136/bmj.38273.626655.63).

121. Caicoya M. Fish consumption and stroke: A community case-control study in Asturias, Spain. Neuroepidemiology 2002;21(3):107–14.

122. Koutki P, Chen TC, Holick MF. Vitamin D intoxication associated with an over-the-counter supplement. N Engl J Med 2001;345(1):66–7.

123. Belluzzi A, Brignola C, Campieri M, et al. Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn’s disease patients. Dig Dis Sci 1994;39(12):2589–94.

124. Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association, Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106(21):2747–57.

125. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Food Safety and Applied Nutrition (CFSAN). Guidance for clinical investigators, sponsors, and IRBs. Investigational new drug applications (INDs)—determining whether human research studies can be conducted without an IND. 2013. Available at: https://www.fda.gov/downloads/drugs/guidances/ucm229175.pdf. (accessed March 10, 2019).